PARIS, September 16, 2021 / PRNewswire / – Coave Therapeutics (“Coave”), a clinical-stage biotechnology company focused on the development of life-changing gene therapies for rare diseases of the eye and the CNS (central nervous system), concluded a exclusive license, a co-development and marketing agreement with Théa, the European leader in Pharma specializing in ophthalmology. The agreement covers Coave’s leading experimental gene therapy candidate, CTx-PDE6b (formerly HORA-PDE6b) for patients with retinitis pigmentosa (RP) associated with PDE6b, an inherited retinal disease (IRD).
“We are delighted to sign this agreement with Théa for CTx-PDE6b, our most advanced candidate, which represents a new innovative gene therapy for people with retinitis pigmentosa”, noted Rodolphe Clerval, CEO of Coave. “Théa is a leading European pharmaceutical company in the field of ophthalmology with world-class development expertise and commercial capabilities in major markets around the world. We are very excited about the potential of CTx-PDE6b and look forward to building a fruitful relationship with Théa as we advance this new candidate into clinical development. ”
Under the terms of the agreement, Coave will receive an upfront payment and an equity investment of € 10 million from Théa. Coave is also eligible to receive up to € 65 million for the completion of specific clinical, regulatory and commercial development milestones with CTx-PDE6b.
Coave and Théa will co-develop CTx-PDE6b as part of the joint agreement. Coave retains the rights to commercialize CTx-PDE6b in the United States and Théa receives an exclusive license to commercialize CTx-PDE6b in Europe (EU27), Ukraine, Turkey, Russia and North Africa. Coave will be eligible to receive double-digit royalties on net sales generated in these territories.
“We are delighted with this alliance between two French companies, a biotech specialized in gene therapy and a specialty pharma focused on ophthalmology. As such, our two companies are very complementary. noted Jean-Frédéric Chibret, Chairman of the Théa Group. “Théa already has a large portfolio of products covering most of the ophthalmology therapeutic classes. This partnership confirms our desire to enter the field of the retina, as well as to position ourselves in the new gene therapy market.
CTx-PDE6b is a novel first-class adeno-associated virus (AAV) gene therapy designed to deliver a complete, unmutated copy of the functional human PDE6b gene into the subretinal space. Dysfunction of the PDE6 protein, and in particular of its PDE6β subunit, ultimately leads to the death of the photoreceptor cells in rods, then of the photoreceptor cells in cones, leading to blindness. There is currently no approved treatment for RA associated with PDE6b.
Treatment with CTx-PDE6b can significantly delay or arrest retinal degeneration in PDE6β-deficient patients and delay or prevent the onset of blindness.
CTx-PDE6b is currently in a Phase I / II clinical trial to determine the safety and efficacy of gene therapy.
Barny Avocats advised Coave Therapeutics on the transaction.
About Coave Therapeutics
Coave Therapeutics is a clinical-stage biotechnology company focused on the development of life-changing gene therapies for rare eye and CNS (central nervous system) diseases.
Coave Therapeutics’ next-generation AAV-Ligand Conjugate (“ALIGATER”) platform enables targeted delivery and enhanced gene transduction to improve the efficacy of advanced gene therapies for rare diseases.
The Company is advancing a pipeline of new therapies targeting rare eye and brain diseases where targeted gene therapy using AAV-Ligand has the potential to be most effective.
Coave Therapeutics, headquartered at Paris, France), is supported by the main international investors in life sciences and strategic Seroba Life Sciences, Théa Open Innovation, eureKARE, Fund +, Omnes Capital, V-Bio Ventures, Kurma Partners, Idinvest, GO Capital, Sham Innovation Santé / Turenne.
About Théa and Théa Open Innovation
Théa is a leading independent European pharmaceutical company specializing in the research, development and commercialization of eye care products.
Situated at Clermont-Ferrand, this family business continued its development by opening more than 30 subsidiaries and offices in Europe, Russia, North Africa, North and South America. Its products are available in more than 70 countries.
Théa Open Innovation (TOI) is a sister company of Théa. TOI’s mission is to establish partnerships with companies and universities to help bring to market the most innovative products in ophthalmology.
For more information visit: https://www.laboratoires-thea.com/fr
Rodolphe Clerval, CEO
Sylvie Berrebi, Eleanor Perkin, Mark Swallow PhD
Phone: +44 (0) 7714 306525
SOURCE Coave Therapeutics